EVO (Evotec SE) Other Long-Term Liabilities : $55.4 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Evotec SE Other Long-Term Liabilities?

Evotec SE's other long-term liabilities for the quarter that ended in Sep. 2024 was $55.4 Mil.

Evotec SE's quarterly other long-term liabilities increased from Mar. 2024 ($19.3 Mil) to Jun. 2024 ($63.6 Mil) but then declined from Jun. 2024 ($63.6 Mil) to Sep. 2024 ($55.4 Mil).

Evotec SE's annual other long-term liabilities declined from Dec. 2021 ($20.9 Mil) to Dec. 2022 ($18.4 Mil) but then increased from Dec. 2022 ($18.4 Mil) to Dec. 2023 ($19.0 Mil).

Evotec SE Other Long-Term Liabilities Historical Data

The historical data trend for Evotec SE's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Other Long-Term Liabilities Chart

Evotec SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

25.04

25.47

20.89

18.44

19.03

Evotec SE Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Long-Term Liabilities	Get a 7-Day Free Trial															18.74	19.03	19.34	63.64	55.44

Evotec SE Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Evotec SE Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Evotec SE's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

EVOTF:USA 1EVT:Italy 0IRF:UK EVT:Germany EVT:Germany EVT:Germany EVT:Germany EVTA:Germany EVT:Bulgaria EVT:Austria

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.